Curatis Holding AG (CH:CURN)
:CURN
Want to see CH:CURN full AI Analyst Report?
Top Page
Curatis Holding AG
(CURN)
Select Model
Select Model
Rating:53Neutral
Price Target:
CHF25.00
Action:Reiterated
Date:04/03/26
The score is held back primarily by continued losses and ongoing cash burn despite improving revenue and margins. A debt-free balance sheet provides support, and technicals show a solid uptrend, but the negative P/E and lack of dividend underscore that profitability has not yet been established.
Positive Factors
Revenue & Margin Improvement
A ~57% revenue rebound and margin expansion to ~26% show improving product adoption and pricing. Sustained top-line momentum and rising gross margins create operating leverage potential, bolstering the company's ability to move toward durable profitability over several quarters if trends persist.
Negative Factors
Negative Cash Flow
Persistent operating and free cash flow deficits that worsened in 2025 indicate ongoing cash burn. This creates lasting dependency on external funding, risks dilution or restricted spending, and can constrain the firm's ability to sustain development and commercialization without secured capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Margin Improvement
A ~57% revenue rebound and margin expansion to ~26% show improving product adoption and pricing. Sustained top-line momentum and rising gross margins create operating leverage potential, bolstering the company's ability to move toward durable profitability over several quarters if trends persist.
Read all positive factors
Curatis Holding AG (CURN) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF122.15M
Dividend YieldN/A
Average Volume (3M)1.42K
Price to Earnings (P/E)―
Beta (1Y)-1.04
Revenue Growth56.61%
EPS Growth70.90%
CountryCH
Employees7
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding5,155,765
10 Day Avg. Volume1,205
30 Day Avg. Volume1,417
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)1.30
Price to Sales (P/S)5.54
P/FCF Ratio-23.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.79
Revenue Forecast (FY)CHF99.00M
Curatis Holding AG Business Overview & Revenue Model
Company Description
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialize...
How the Company Makes Money
null...
Curatis Holding AG Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
74
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.65M | 10.80M | 6.90M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 276.00K | 2.84M | 1.59M | 0.00 | 0.00 | 0.00 |
| EBITDA | -431.00K | -1.13M | -4.34M | -38.34M | -38.37M | -130.00K |
| Net Income | -470.00K | -1.42M | -4.34M | -49.38M | -34.73M | 137.00K |
Balance Sheet | ||||||
| Total Assets | 2.41M | 55.96M | 55.54M | 120.00K | 14.05M | 136.00K |
| Cash, Cash Equivalents and Short-Term Investments | 894.00K | 1.87M | 3.01M | 9.00K | 1.34M | 124.00K |
| Total Debt | 485.00K | 0.00 | 0.00 | 133.00K | 3.00M | 429.00K |
| Total Liabilities | 2.64M | 9.88M | 9.94M | 432.00K | 7.29M | 536.00K |
| Stockholders Equity | -228.00K | 46.08M | 45.60M | -312.00K | 6.75M | -400.00K |
Cash Flow | ||||||
| Free Cash Flow | -331.00K | -2.53M | -825.00K | -1.89M | -4.66M | -359.00K |
| Operating Cash Flow | -331.00K | -1.31M | -825.00K | -1.89M | -4.65M | -359.00K |
| Investing Cash Flow | 298.50K | -1.22M | 4.01M | -6.00K | 5.48M | 0.00 |
| Financing Cash Flow | -11.50K | 1.38M | -183.00K | 558.00K | 392.00K | 420.00K |
Curatis Holding AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
Curatis Holding AG Corporate Events
Curatis Shareholders Back All AGM Proposals, Re-elect Entire Board
May 22, 2026
Curatis Holding AG reported that shareholders at its Annual General Meeting approved all board proposals, including the 2025 annual report, financial statements, and compensation packages for the board and management. Auditor Forvis Mazars was rea...
Curatis Raises CHF 3 Million to Accelerate Phase III Development of Lead Orphan Drug
May 22, 2026
Curatis Holding AG has secured a CHF 3.0 million private placement from a strategic Swiss investor via a convertible instrument that can later be turned into shares sourced from the firm’s conditional capital. The instrument is set on prevai...
Curatis Boosts 2025 Revenue and Advances Corticorelin With Japan Deal
Mar 24, 2026
Curatis Holding AG reported a 57% jump in 2025 revenues to CHF 10.8 million, driven by 13% organic growth in its distribution business and new product contracts, while narrowing its net loss to CHF 1.4 million. The company ended the year with CHF ...
Curatis Licenses Brain Edema Drug Corticorelin to Neupharma for Japanese Market
Mar 11, 2026
Curatis Holding AG has signed an exclusive license and development agreement with Tokyo-based Neupharma Co., Ltd. granting Neupharma rights to develop and commercialize Curatis’ lead candidate corticorelin (C-PTBE-01) for peritumoral brain e...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.